Literature DB >> 3052962

Renal osteodystrophy and aluminum bone disease in CAPD patients.

R Gokal1.   

Abstract

Renal failure is frequently associated with osteodystrophia due to secondary hyperparathyreoidism and/or increased aluminum intake. The problem of hypercalcemia and hyperphosphatemia can more easily controlled by CAPD than by hemodialysis. Total serum and ionized calcium levels are rapidly normalized by a CAPD regime of four 2-1 exchanges with 1.75 mmol/l Ca. Under the same CAPD regime 250-300 mg phosphate are removed per day. Depending on the ingestion of phosphate, 100-200 mg phosphate per day remain to be removed by phosphate binding agents. Since the main source of aluminum in CAPD patients is oral ingestion of aluminum-containing phosphate binders, serum levels should be regulated by diet and calcium carbonate. To suppress PTH secretion serum ionized calcium levels need to be maintained at the upper limit of normal. This can also be achieved by the use of oral calcium carbonate. Vitamin D or analogs should be prescribed only when clinically indicated by persistent hypocalcemia, osteitis fibrosa or non-aluminum related osteomalacia.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3052962

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  3 in total

1.  Risk factors and consequences of hyperaluminemia in a peritoneal dialysis cohort.

Authors:  Valery Lavergne; Marc Ghannoum; Megan Christie; Van Vo; Paul W Tam; Robert Ting; Tabo Sikaneta
Journal:  Perit Dial Int       Date:  2012-08-01       Impact factor: 1.756

2.  Blood Aluminum Levels in Patients with Hemodialysis and Peritoneal Dialysis.

Authors:  Po-Hsun Chuang; Kai-Fan Tsai; I-Kuan Wang; Ya-Ching Huang; Lan-Mei Huang; Shou-Hsuan Liu; Cheng-Hao Weng; Wen-Hung Huang; Ching-Wei Hsu; Wen-Chin Lee; Tzung-Hai Yen
Journal:  Int J Environ Res Public Health       Date:  2022-03-24       Impact factor: 3.390

3.  Cancer risk following organ transplantation: a nationwide cohort study in Sweden.

Authors:  J Adami; H Gäbel; B Lindelöf; K Ekström; B Rydh; B Glimelius; A Ekbom; H-O Adami; F Granath
Journal:  Br J Cancer       Date:  2003-10-06       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.